|
1
|
Orbach D, Rey A, Cecchetto G, Oberlin O,
Casanova M, Thebaud E, Scopinaro M, Bisogno G, Carli M and Ferrari
A: Infantile fibrosarcoma: Management based on the European
experience. J Clin Oncol. 28:318–323. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Orbach D, Brennan B, De Paoli A, Gallego
S, Mudry P, Francotte N, van Noesel M, Kelsey A, Alaggio R,
Ranchère D, et al: Conservative strategy in infantile fibrosarcoma
is possible: The European paediatric soft tissue sarcoma study
group experience. Eur J Cancer. 57:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chung EB and Enzinger FM: Infantile
fibrosarcoma. Cancer. 38:729–739. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Davis JL, Lockwood CM, Stohr B, Boecking
C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette
M, et al: Expanding the spectrum of pediatric NTRK-rearranged
mesenchymal tumors. Am J Surg Pathol. 43:435–445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coffin CM, Jaszcz W, O'Shea PA and Dehner
LP: So-called congenital-infantile fibrosarcoma: Does it exist and
what is it? Pediatr Pathol. 14:133–150. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rudzinski ER, Lockwood CM, Stohr BA,
Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW and Davis
JL: Pan-Trk immunohistochemistry identifies NTRK rearrangements in
pediatric mesenchymal tumors. Am J Surg Pathol. 42:927–935. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pavlick D, Schrock AB, Malicki D, Stephens
PJ, Kuo DJ, Ahn H, Turpin B, Allen JM, Rosenzweig M, Badizadegan K,
et al: Identification of NTRK fusions in pediatric mesenchymal
tumors. Pediatr Blood Cancer. 64:e264332017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davis JL, Vargas SO, Rudzinski ER, López
Marti JM, Janeway K, Forrest S, Winsnes K, Pinto N, Yang SE,
VanSandt M, et al: Recurrent RET gene fusions in paediatric spindle
mesenchymal neoplasms. Histopathology. 76:1032–1041. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Flucke U, van Noesel MM, Wijnen M, Zhang
L, Chen CL, Sung YS and Antonescu CR: TFG-MET fusion in an
infantile spindle cell sarcoma with neural features. Genes
Chromosomes Cancer. 56:663–667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Penning AJ, Al-Ibraheemi A, Michal M,
Larsen BT, Cho SJ, Lockwood CM, Paulson VA, Liu YJ, Plank L,
Fritchie K, et al: Novel BRAF gene fusions and activating point
mutations in spindle cell sarcomas with histologic overlap with
infantile fibrosarcoma. Mod Pathol. 34:1530–1540. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kao YC, Fletcher CDM, Alaggio R, Wexler L,
Zhang L, Sung YS, Orhan D, Chang WC, Swanson D, Dickson BC and
Antonescu CR: Recurrent BRAF gene fusions in a subset of pediatric
spindle cell sarcomas: Expanding the genetic spectrum of tumors
with overlapping features with infantile fibrosarcoma. Am J Surg
Pathol. 42:28–38. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El-Osta H, Falchook G, Tsimberidou A, Hong
D, Naing A, Kim K, Wen S, Janku F and Kurzrock R: BRAF mutations in
advanced cancers: Clinical characteristics and outcomes. PLoS One.
6:e258062011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ross JS, Wang K, Chmielecki J, Gay L,
Johnson A, Chudnovsky J, Yelensky R, Lipson D, Ali SM, Elvin JA, et
al: The distribution of BRAF gene fusions in solid tumors and
response to targeted therapy. Int J Cancer. 138:881–890. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Subbiah V, Westin SN, Wang K, Araujo D,
Wang WL, Miller VA, Ross JS, Stephens PJ, Palmer GA and Ali SM:
Targeted therapy by combined inhibition of the RAF and mTOR kinases
in malignant spindle cell neoplasm harboring the KIAA1549-BRAF
fusion protein. J Hematol Oncol. 7:82014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitsis D, Opyrchal M, Zhao Y, Kane Iii JM,
Cheney R and Salerno KE: Exceptional clinical response to
BRAF-targeted therapy in a patient with metastatic sarcoma. Cureus.
7:e4392015.PubMed/NCBI
|
|
17
|
Wegert J, Vokuhl C, Collord G, Del
Castillo Velasco-Herrera M, Farndon SJ, Guzzo C, Jorgensen M,
Anderson J, Slater O, Duncan C, et al: Recurrent intragenic
rearrangements of EGFR and BRAF in soft tissue tumors of infants.
Nat Commun. 9:23782018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hughes CE, Correa H, Benedetti DJ, Smith
B, Sumegi J and Bridge J: Second report of PDE10A-BRAF fusion in
pediatric spindle cell sarcoma with infantile fibrosarcoma-like
morphology suggesting PDE10A-BRAF fusion is a recurrent event.
Pediatr Dev Pathol. 24:554–558. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Wu G, Miller CP, Tatevossian RG,
Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, et
al: Whole-genome sequencing identifies genetic alterations in
pediatric low-grade gliomas. Nat Genet. 45:602–612. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones DT, Kocialkowski S, Liu L, Pearson
DM, Bäcklund LM, Ichimura K and Collins VP: Tandem duplication
producing a novel oncogenic BRAF fusion gene defines the majority
of pilocytic astrocytomas. Cancer Res. 68:8673–8677. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Selt F, van Tilburg CM, Bison B, Sievers
P, Harting I, Ecker J, Pajtler KW, Sahm F, Bahr A, Simon M, et al:
Response to trametinib treatment in progressive pediatric low-grade
glioma patients. J Neurooncol. 149:499–510. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perreault S, Larouche V, Tabori U, Hawkin
C, Lippé S, Ellezam B, Décarie JC, Théoret Y, Métras MÉ, Sultan S,
et al: A phase 2 study of trametinib for patients with pediatric
glioma or plexiform neurofibroma with refractory tumor and
activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer.
19:12502019. View Article : Google Scholar : PubMed/NCBI
|
